Lilly Gets Approval For Its Alzheimer's Disease Drug Kisunla
pharmaphorum · 8h
Lilly gets second approval, in Japan, for Alzheimer's drug
Kisunla (donanemab) is the second in a new generation of amyloid-targeting medicines to reach the Japanese market after Eisai and Biogen's Leqembi (lecanemab), which was approved by the country's Ministry of Health, Labour and Welfare (MHLW) a year ago.
The Pharma Letter · 3h
Second approval in major market for Lilly’s Alzheimer’s drug
Eli Lilly's Kisunla has been approved in Japan for early symptomatic Alzheimer's disease, following its US approval in July 2024. Administered via IV infusion, it targets patients with mild cognitive impairment and dementia linked to amyloid pathology.
YAHOO!Finance · 1d
Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market
The Ministry of Health, Labour and Welfare Japan approved Eli Lilly And Co’s (NYSE:LLY) Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD,
MarketWatch · 1d
Eli Lilly Gets Japan OK for Kisunla Alzheimer's Disease Drug
Eli Lilly on Tuesday said Japan's Ministry of Health, Labour and Welfare Japan approved Kisunla for adults with early symptomatic Alzheimer's, including those with mild cognitive impairment as well as people with the mild dementia stage of the memory-robbing disease.
PipelineReview.com · 4h
Lilly’s Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer’s Disease
Kisunla™ (donanemab-azbt), pronounced kih-SUHN-lah, is used to treat adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Business Insider · 1d
Lilly Gets Approval For Its Alzheimer's Disease Drug Kisunla In Japan
Tuesday said its Kisunla for the treatment of adults with early symptomatic Alzheimer's disease has been approved by the Ministry of Health, Labour and Welfare Japan. The approval was based on results from TRAILBLAZER-ALZ 2 Phase 3 study,
Results that may be inaccessible to you are currently showing.
Hide inaccessible results